Advertisement

Immunocytokines for Cancer Immunotherapy

  • Paul M. Sondel
  • Steven D. Gillies
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

Immunologic approaches to cancer therapy rely on two distinct capabilities of the immune system: targeting the tumor microenvironment by recognizing molecules expressed to a greater extent on tumor cells than normal cells and generating immune responses that can kill tumor cells (1,2). Immunocytokines, which are fusion proteins composed of a recombinant monoclonal antibody and a cytokine, capitalize on both of these capabilities by combining the ability of tumor-specific antibodies selectively to target tumors with the broad-based immunomodulatory activities of cytokines (3). This chapter describes the rationale for development of immunocytokines for cancer and discusses preclinical and clinical data on specific immunocytokines being investigated as potential cancer therapies.

Keywords

Natural Killer Cell SCID Mouse General Vaccine Immunotherapy Strategy Recombinant Monoclonal Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sondel PM, Hank JA. Antibody-directed, effector cell-mediated tumor destruction. Hem Oncol Clinical North Am 2001; 15:703–721.CrossRefGoogle Scholar
  2. 2.
    Cheng JD, Rieger PT, von Mehren M, et al. Recent advances in immunotherapy and monoclonal antibody treatment of cancer. Semin Oncol Nurs 2000; 16(Suppl 1):2–12.PubMedCrossRefGoogle Scholar
  3. 3.
    Lode HN, Xiang R, Becker JC, et al. Immunocytokines: a promising approach to cancer immunotherapy. Pharmacol Ther 1998; 80:277–292.PubMedCrossRefGoogle Scholar
  4. 4.
    Reff ME, Camer K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83:434–445.Google Scholar
  5. 5.
    Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody in patients with recurrent B-cell lymphoma. Blood 1994; 84:2457–2466.PubMedGoogle Scholar
  6. 6.
    Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 1997; 90:2188–2195.PubMedGoogle Scholar
  7. 7.
    Harries M, Smith I. The development and clinical use of trastuzumab. Endocr Relat Cancer 2002; 9: 75–85.PubMedCrossRefGoogle Scholar
  8. 8.
    George AJ, Spooner RA, Epenetos AA. Applications of monoclonal antibodies in clinical oncology. Immunol Today 1994; 15:559–561.PubMedCrossRefGoogle Scholar
  9. 9.
    Ghetie MA, Vitetta ES. Recent developments in immunotoxin therapy. Curr Opin Immunol 1994; 6:707–714.PubMedCrossRefGoogle Scholar
  10. 10.
    Goldenberg DM, Larson SM, Reisfeld RA, et al. Targeting cancer with radiolabeled antibodies. Immunol Today 1995; 16:261–264.PubMedCrossRefGoogle Scholar
  11. 11.
    Mocellin S, Wang E, Marincola FM. Cytokines and immune response in the tumor microenvironment. J Immunother 2001; 24:392–407.CrossRefGoogle Scholar
  12. 12.
    Keilholz U, Stoter G, Punt CJ, et al. Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. Cancer J Sci Am 1997; 3(Suppl 1):22–28.Google Scholar
  13. 13.
    Baluna R, Vitetta ES. Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology 1997; 37:117–132.PubMedCrossRefGoogle Scholar
  14. 14.
    Veltri S, Smith JW. Interleukin-1 trials in cancer patients: a review of the toxicity, antitumor, and hematopoietic effects. Stem Cells 1996; 14:164–176.PubMedCrossRefGoogle Scholar
  15. 15.
    Lentsch AB, Miller FN, Edwards MJ. Mechanisms of leukocyte-mediated tissue injury induced by interleukin-2. Cancer Immunol Immunother 1999; 47:243–248.PubMedCrossRefGoogle Scholar
  16. 16.
    Gillies SD, Reilly EB, Lo K-M, et al. Antibody-targeted interleukin-2 stimulates T cell killing of autologous tumor cells. Proc Natl Acad Sci USA 1992; 89:1428–1432.PubMedCrossRefGoogle Scholar
  17. 17.
    Reisfeld RA, Gillies SD. Antibody-interleukin-2 fusion proteins: a new approach to cancer therapy. J Clin Lab Anal 1996; 10:160–166.PubMedCrossRefGoogle Scholar
  18. 18.
    Parry JL. hu14.18-IL-2 Investigator’s Brochure. Version 2. EMD Pharmaceuticals, October 2001.Google Scholar
  19. 19.
    Sabzevari H, Gillies SD, Mueller BM, et al. A recombinant antibody-interleukin-2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci USA 1994; 91:9626–9630.PubMedCrossRefGoogle Scholar
  20. 20.
    Kendra K, Gan J, Ricci M, et al. Pharmacokinetics and stability of the 14.18-IL-2 fusion protein in mice. Cancer Immunol Immunother 1999; 48:219–229.PubMedCrossRefGoogle Scholar
  21. 21.
    Gan J, Kendra, K, Ricci M, et al. Specific ELISA systems for quantitation of antibody-cytokine fusion proteins. Clin Diagn Lab Immunol 1999; 6:236–242.PubMedGoogle Scholar
  22. 22.
    Reisfeld RA, Becker JC, Gillies SD. Immunocytokines: a new approach to immunotherapy of melanoma. Melanoma Res 1997; 7(Suppl 2):S99-S106.CrossRefGoogle Scholar
  23. 23.
    Pancook JD, Becker JC, Gillies SD, et al. Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2. Cancer Immunol Immunother 1996; 42:88–92.PubMedCrossRefGoogle Scholar
  24. 24.
    Becker JC, Pancook JD, Gillies SD, et al. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin-2 fusion proteins. Proc Natl Acad Sci USA 1996; 93:2702–2707.PubMedCrossRefGoogle Scholar
  25. 25.
    Becker JC, Varki N, Gillies SD, et al. An antibody-interleukin-2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc Natl Acad Sci USA 1996; 93:7826–7831.PubMedCrossRefGoogle Scholar
  26. 26.
    Lode HN, Xiang R, Pertl U, et al. Melanoma immunotherapy by targeted IL-2 depends on CD4+ T cell help mediated by CD40/CD4OL interaction. J Clin Invest 2000; 105:1623–1630.PubMedCrossRefGoogle Scholar
  27. 27.
    Becker JC, Pancook JD, Gillies SD, et al. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med 1996; 183:2361–2366.PubMedCrossRefGoogle Scholar
  28. 28.
    Becker JC, Varki N, Gillies SD, et al. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J Clin Invest 1996; 98:2801–2804.PubMedCrossRefGoogle Scholar
  29. 29.
    Neal Z, Rakhmilevich A, Hank J, et al. hu14.18-IL-2 immunocytokine plus systemic IL-2 combinatorial therapy: prevention of tumor escape. Abstract. Society for Biological Therapy 17th Annual Meeting, 2002.Google Scholar
  30. 30.
    King D, Albertini M, Schalch H, et al. Phase I/IB trial of the immunocytokine hu14.18-IL-2 in patients with metastatic melanoma. Abstract 62. American Society of Clinical Oncology Annual Meeting, 2002. Available at www.asco.org/asco/publications/abstract print view. Accessed 9 October 2002.Google Scholar
  31. 31.
    King D, Albertini M, Schalch H, et al. Phase I/IB trial of the immunocytokine hu14.18-IL-2 in patients with GD2-positive tumors. Abstract. Society for Biological Therapy 16th Annual Meeting Oral Abstracts, 2001. Available at www.socbiother.com/meetings/bethesda1finalHTML/abstracts5.htm. Accessed 9 October 2002.Google Scholar
  32. 32.
    King D, Albertini M, Schalch H, et al. Clinical and immunological investigation of the immunocytokine EMD 273063 (hu14.18-IL-2) in subjects with metastatic or recurrent melanoma. Abstract. Society for Biological Therapy 17th Annual Meeting, 2002.Google Scholar
  33. 33.
    Frost JD, Ettinger LJ, Hank JA, et al. Phase I/IB trial of murine monoclonal anti-GD2 antibody 14.Ga plus IL-2 in children with refractory neuroblastoma: a report of the Children’s Cancer Group. Cancer 1997; 80:317–333.PubMedCrossRefGoogle Scholar
  34. 34.
    Xiang R, Lode HN, Dolman CS, et al. Elimination of established murine colon carcinoma metastases by antibody-interleukin-2 fusion protein therapy. Cancer Res 1997; 57:4948–4955.PubMedGoogle Scholar
  35. 35.
    Holden SA, Lan Y, Pardo AM, et al. Augmentation of antitumor activity of an antibody-interleukin-2 immunocytokine with chemotherapeutic agents. Clin Cancer Res 2001; 7:2862–2869.PubMedGoogle Scholar
  36. 36.
    Dolman CS, Mueller BM, Lode HN, et al. Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin-2 immunocytokine therapy. Clin Cancer Res 1998; 4:2551–2557.PubMedGoogle Scholar
  37. 37.
    Field E. huKS-IL-2 Investigator’s Brochure. Version 4. EMD Pharmaceuticals, September 2002.Google Scholar
  38. 38.
    Lode JN, Moehler T, Xiang R, et al. Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. Proc Natl Acad Sci USA 1999; 96:1591–1596.PubMedCrossRefGoogle Scholar
  39. 39.
    Xiang R, Lode HN, Gillies SD, et al. T cell memory against colon carcinoma is long-lived in the absence of antigen. J Immunol 1999; 163:3676–3683.PubMedGoogle Scholar
  40. 40.
    Imboden M, Murphy KR, Rakhmilevich AL, et al. The level of MHC Class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy. Cancer Res 2001; 61:1500–1507.PubMedGoogle Scholar
  41. 41.
    Weber R, Refern C, Gutheil J, et al. Phase I trial of huKS-IL-2 immunocytokine in patients with prostate carcinoma: clinical, pharmacokinetic, and biological pharmacodynamic results. Abstract 1033. American Society of Clinical Oncology annual meeting, 2001. Available at www.asco.org/asco/publications/ abstract_print_view. Accessed 9 October 2002.Google Scholar
  42. 42.
    Finke LH, Haunschild J, Kovar A, et al. Early-phase clinical development of the immunocytokine EMD 273066 (huKS-IL-2): laboratory and safety findings in patients with prostate cancer. Abstract. Society for Biological Therapy 16th Annual Meeting Oral Abstracts, 2001. Available at www.socbiother.com/ meetings/bethesda/fina1HTML/abstracts6.htm. Accessed 9 October 2002.Google Scholar
  43. 43.
    Malaguarnera M, Ferlito L, Gulizia G, et al. Use of interleukin-2 in advanced renal carcinoma: metaanalysis and review of the literature. Eur J Clin Pharmacol 2001; 57:267–273.PubMedCrossRefGoogle Scholar
  44. 44.
    Fleckenstein G, Osmers R, Pubhta J. Monoclonal antibodies in solid tumours: approaches to therapy with emphasis on gynaecological cancer. Med Oncol 1998; 15:212–221.PubMedCrossRefGoogle Scholar
  45. 45.
    Gillies SD, Lan Y, Wesolowski JS, et al. Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases. J Immunol 1996; 160:6195–6203.Google Scholar
  46. 46.
    Gillies SD, Lan Y, Brunkhorst B, et al. Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer. Cancer Immunol Immunother 2002; 51:449–460.PubMedCrossRefGoogle Scholar
  47. 47.
    Batova A, Kamps A, Gillies SD, et al. The ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro. Clin Cancer Res 1999; 5:4259–4263.PubMedGoogle Scholar
  48. 48.
    Metelitsa LS, Gillies SD, Super M, et al. Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcyRII and Mac-1 for enhanced effector cell adhesion and azurophil granule exocytosis. Blood 2002; 99:4166–4173.PubMedCrossRefGoogle Scholar
  49. 49.
    Ragnhammar P, Masucci G, Frodin JE, et al. Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17–1A and granulocyte-macrophage-colony stimulating factor. Cancer Immunol Immunother 1992: 35:158–164.PubMedCrossRefGoogle Scholar
  50. 50.
    Mellstedt H, Frodin JE, Ragnhammar P, et al. Therapy of colorectal carcinoma with monoclonal antibodies alone and in combination with granulocyte monocyte-colony stimulating factor. Acta Oncol 1991; 30:923–931.PubMedCrossRefGoogle Scholar
  51. 51.
    Ya A, Batova A, Alvarado C, et al. Usefulness of a chimeric anti-GD2 and GM-CSF for refractory neuroblastoma: a POG phase II study. Proc Am Soc Clin Oncol 1997; 16:1846.Google Scholar
  52. 52.
    Homick JL, Khaawli LA, Hu P, et al. Pretreatment with a monoclonal antibody/IL-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors. Clin Cancer Res 1999; 5:51–60.Google Scholar
  53. 53.
    Penichet ML, Morrison SL. Antibody-cytokine fusion proteins for the therapy of cancer. J Immunol Methods 2001; 248:91–101.PubMedCrossRefGoogle Scholar
  54. 54.
    Penichet ML, Dela Cruz JS, Shin SU, et al. A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors. Hum Antibodies 2001; 10:43–49.PubMedGoogle Scholar
  55. 55.
    Lode HN, Xiang R, Duncan SR, et al. Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12. Proc Natl Acad Sci USA 1999; 96:8591–8596.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2004

Authors and Affiliations

  • Paul M. Sondel
  • Steven D. Gillies

There are no affiliations available

Personalised recommendations